Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).

被引：0
|
作者：
Medioni, J.
Ferrero, J.
Deplanque, G.
Maurina, T.
Rodier, J. P.
Raymond, E.
Allyon, J.
Renaux, S.
Dufour-Lamartinie, J.
Oudard, S.
机构：
[1] Georges Pompidou European Hosp, Paris, France
[2] Ctr Antoine Lacassagne, F-06054 Nice, France
[3] Grp Hosp St Joseph, Paris, France
[4] Jean Minjoz Hosp, Besancon, France
[5] Hop Xavier Bichat, Paris, France
[6] Beaujon Univ Hosp, Clichy, France
[7] Hybrigenics, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4605
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Hotte, Sebastien J.
    Yu, Evan Y.
    Tu, Dongsheng
    Eigl, Bernhard J.
    Tannock, Ian
    Saad, Fred
    North, Scott
    Powers, Jean
    Gleave, Martin E.
    Eisenhauer, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4247 - 4254
  • [42] Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases
    Lee, Richard J.
    Michaelson, M. Dror
    Saylor, Philip James
    Gurski, Carol Ann
    Rothenberg, Stephen M.
    Miyamoto, David Tomoaki
    Maheswaran, Shyamala
    Haber, Daniel A.
    Goldin, Jonathan G.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer
    Porsch, Markus
    Ulrich, Matthias
    Wendler, Johann Jakob
    Liehr, Uwe-Bernd
    Reiher, Frank
    Janitzky, Andreas
    Baumunk, Daniel
    Schindele, Daniel
    Seseke, Florian
    Lux, Anke
    Schostak, Martin
    CHEMOTHERAPY, 2014, 60 (02) : 129 - 134
  • [44] A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial
    van Dodewaard-de Jong, Joyce M.
    de Klerk, John M. H.
    Bloemendal, Haiko J.
    Oprea-Lager, Daniela E.
    Hoekstra, Otto S.
    van den Berg, H. Pieter
    Los, Maartje
    Beeker, Aart
    Jonker, Marianne A.
    O'Sullivan, Joe M.
    Verheul, Henk M. W.
    van den Eertwegh, Alfons J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) : 1319 - 1327
  • [45] A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial
    Joyce M. van Dodewaard-de Jong
    John M. H. de Klerk
    Haiko J. Bloemendal
    Daniela E. Oprea-Lager
    Otto S. Hoekstra
    H. Pieter van den Berg
    Maartje Los
    Aart Beeker
    Marianne A. Jonker
    Joe M. O’Sullivan
    Henk M. W. Verheul
    Alfons J. M. van den Eertwegh
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1319 - 1327
  • [46] Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer
    Feby Mardjuadi
    Jacques Medioni
    Joseph Kerger
    Lionel D’Hondt
    Jean-Luc Canon
    Lionel Duck
    Flora Musuamba
    Stephane Oudard
    Marylene Clausse
    Anne Moxhon
    Jean-Pascal Machiels
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 293 - 303
  • [47] Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
    Kongsted, Per
    Borch, Troels Holz
    Ellebaek, Eva
    Iversen, Trine Zeeberg
    Andersen, Rikke
    Met, Ozcan
    Hansen, Morten
    Lindberg, Henriette
    Sengelov, Lisa
    Svane, Inge Marie
    CYTOTHERAPY, 2017, 19 (04) : 500 - 513
  • [48] Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-na⟨ve patients with metastatic castration-resistant prostate cancer
    Mardjuadi, Feby
    Medioni, Jacques
    Kerger, Joseph
    D'Hondt, Lionel
    Canon, Jean-Luc
    Duck, Lionel
    Musuamba, Flora
    Oudard, Stephane
    Clausse, Marylene
    Moxhon, Anne
    Machiels, Jean-Pascal
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 293 - 303
  • [49] High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study
    Shamseddine, Ali
    Farhat, Fadi S.
    Elias, Elias
    Khauli, Raja B.
    Saleh, Ahmad
    Bulbul, Mohammad A.
    UROLOGIA INTERNATIONALIS, 2013, 90 (01) : 56 - 61
  • [50] Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Piera Federico
    Carmine D’Aniello
    Pasquale Rescigno
    Carla Cavaliere
    Livio Puglia
    Matteo Ferro
    Vincenzo Altieri
    Sisto Perdonà
    Sabino De Placido
    Giuseppe Di Lorenzo
    Cancer Chemotherapy and Pharmacology, 2011, 67 (6) : 1463 - 1463
12345